|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIAA1328 |
Gene summary for KIAA1328 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIAA1328 | Gene ID | 57536 |
| Gene name | KIAA1328 | |
| Gene Alias | KIAA1328 | |
| Cytomap | 18q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q86T90 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57536 | KIAA1328 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.13e-03 | 4.18e-01 | 0.3371 |
| 57536 | KIAA1328 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.71e-02 | 3.87e-01 | 0.343 |
| 57536 | KIAA1328 | RNA-P17T-P17T-6 | Human | Lung | IAC | 4.71e-02 | 3.86e-01 | 0.3385 |
| 57536 | KIAA1328 | RNA-P23T2-P23T2-1 | Human | Lung | MIAC | 2.13e-03 | 7.54e-01 | -0.037 |
| 57536 | KIAA1328 | RNA-P23T2-P23T2-4 | Human | Lung | MIAC | 9.90e-04 | 9.22e-01 | -0.0272 |
| 57536 | KIAA1328 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.49e-13 | 6.24e-01 | -0.2116 |
| 57536 | KIAA1328 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 9.39e-09 | 7.88e-01 | -0.1941 |
| 57536 | KIAA1328 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 4.20e-06 | 5.48e-01 | -0.2107 |
| 57536 | KIAA1328 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.01e-09 | 5.81e-01 | -0.2119 |
| 57536 | KIAA1328 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.10e-09 | 3.71e-01 | -0.0166 |
| 57536 | KIAA1328 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 6.53e-06 | 2.56e-01 | -0.0132 |
| 57536 | KIAA1328 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 3.91e-04 | 2.09e-01 | -0.013 |
| 57536 | KIAA1328 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 5.70e-05 | 2.46e-01 | -0.0121 |
| 57536 | KIAA1328 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.01e-04 | 5.59e-01 | -0.0822 |
| 57536 | KIAA1328 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.35e-06 | 5.45e-01 | -0.0809 |
| 57536 | KIAA1328 | HTA12-15-2 | Human | Pancreas | PDAC | 4.92e-06 | 4.69e-01 | 0.2315 |
| 57536 | KIAA1328 | HTA12-23-1 | Human | Pancreas | PDAC | 1.89e-07 | 7.57e-01 | 0.3405 |
| 57536 | KIAA1328 | HTA12-25-1 | Human | Pancreas | PDAC | 2.44e-10 | 9.01e-01 | 0.313 |
| 57536 | KIAA1328 | HTA12-26-1 | Human | Pancreas | PDAC | 3.84e-16 | 8.50e-01 | 0.3728 |
| 57536 | KIAA1328 | HTA12-29-1 | Human | Pancreas | PDAC | 2.70e-40 | 9.00e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIAA1328 | SNV | Missense_Mutation | novel | c.1268N>A | p.Gly423Glu | p.G423E | Q86T90 | protein_coding | tolerated(0.07) | benign(0.022) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| KIAA1328 | SNV | Missense_Mutation | novel | c.1186C>T | p.Leu396Phe | p.L396F | Q86T90 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| KIAA1328 | SNV | Missense_Mutation | c.1573G>A | p.Ala525Thr | p.A525T | Q86T90 | protein_coding | tolerated(0.06) | possibly_damaging(0.83) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| KIAA1328 | SNV | Missense_Mutation | rs536436186 | c.940N>T | p.Arg314Cys | p.R314C | Q86T90 | protein_coding | tolerated(0.14) | benign(0) | TCGA-AC-A62X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIAA1328 | SNV | Missense_Mutation | c.349N>A | p.Glu117Lys | p.E117K | Q86T90 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD | |
| KIAA1328 | deletion | Frame_Shift_Del | novel | c.1413delN | p.Thr473GlnfsTer2 | p.T473Qfs*2 | Q86T90 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| KIAA1328 | SNV | Missense_Mutation | rs144164188 | c.1543N>C | p.Asp515His | p.D515H | Q86T90 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-ZJ-A8QR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KIAA1328 | SNV | Missense_Mutation | c.935N>T | p.Ala312Val | p.A312V | Q86T90 | protein_coding | tolerated(0.21) | benign(0.069) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KIAA1328 | SNV | Missense_Mutation | rs762601395 | c.1243N>C | p.Ser415Pro | p.S415P | Q86T90 | protein_coding | tolerated(0.25) | benign(0.091) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| KIAA1328 | SNV | Missense_Mutation | c.554N>T | p.Ala185Val | p.A185V | Q86T90 | protein_coding | deleterious(0) | possibly_damaging(0.808) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |